Enclomiphene Dosage Guide: Protocols, Calculator & Safety

Beginner Protocol: Enclomiphene 12.5 mg Monotherapy

This is the entry-level enclomiphene protocol appropriate for men with confirmed secondary hypogonadism, otherwise healthy, who want to trial HPG axis stimulation before considering TRT or more complex regimens.

Prerequisites

1. Two documented morning fasting total testosterone levels below 300 ng/dL (or below laboratory reference range), drawn before 10 AM with repeat confirmation on a separate day.
2. Elevated or inappropriately normal LH/FSH — if LH is already maxed out or high, enclomiphene will not help (this indicates primary hypogonadism which does not respond to SERMs).
3. Normal prolactin — hyperprolactinemia should be worked up and treated first.
4. Normal TSH and free T4 — hypothyroidism can mimic or contribute to low T symptoms.
5. No pituitary pathology — if clinical suspicion (visual field defects, neurological symptoms), MRI of pituitary before starting.
6. Physician oversight — enclomiphene is a prescription drug; obtain through licensed men's health clinic or urology practice.

Baseline Labs (Required)

• Total testosterone, free testosterone (direct or calculated)
• Estradiol (sensitive LC/MS assay preferred)
• LH, FSH
• SHBG
• Prolactin
• TSH, free T4
• CBC with hematocrit
• Comprehensive metabolic panel (CMP)
• Lipid panel
• PSA (if age >40)
• Semen analysis (if fertility is a current or future consideration)

Protocol

• Weeks 1-4: Enclomiphene 12.5 mg by mouth once daily, taken with food in the morning
• Week 4-6: Repeat labs — total T, free T, estradiol, LH, FSH, hematocrit
• Weeks 6-12: Continue 12.5 mg daily if labs and symptoms favorable; consider adjustment based on response
• Week 12: Full repeat lab panel + symptom assessment

Response Categories

1. Good response: Total T 500-800 ng/dL, LH 2-4x baseline, estradiol 20-40 pg/mL, improved symptoms. Continue 12.5 mg daily maintenance.
2. Partial response: Total T 400-500 ng/dL, some symptom improvement. Consider dose increase to 12.5 mg with one 25 mg day weekly, or reassess for other contributing factors.
3. No response: Total T <350 ng/dL after 12 weeks. Consider: primary hypogonadism (check LH — if now high, switch off SERMs), adherence, weight-related issues, or need for alternative approach.
4. Hyper-response: Total T >1,000 ng/dL, significant side effects. Reduce to 12.5 mg every other day or 12.5 mg 3x weekly.

What to Watch For

• Vision changes: any shimmering, floaters, or visual field disturbances → stop immediately, ophthalmology referral
• Mood changes: significant depression, anxiety, irritability → reassess; may need discontinuation
• Persistent headache beyond week 2: consider dose reduction
• Hematocrit >52%: dose reduction; >54%: discontinuation and reassessment
• Estradiol >60 pg/mL with symptoms: consider low-dose AI add-on or dose reduction

Expected Timeline

• Week 1-2: Initial LH/FSH response begins, minimal symptomatic change yet
• Week 3-4: Testosterone begins rising noticeably, some men report early energy/libido improvement
• Week 6-8: Near-maximal testosterone response achieved
• Week 12: Full steady-state, symptom benefits typically evident
• Month 3-6: Semen parameters may improve if baseline subfertile
• Month 6-12: Maintenance phase; stable response if tolerating

Exit Criteria

• Insufficient response after 3 months of optimal dosing
• Intolerable side effects
• Pregnancy achieved (if fertility was the goal and now need is resolved)
• Development of contraindications

Continuation Philosophy

Unlike TRT, enclomiphene therapy can be continued indefinitely if tolerated, with periodic re-assessment. Some clinicians advocate for "drug holidays" every 6-12 months to ensure ongoing need; others note that the intermittent dosing approach (12.5 mg every other day, or 3x weekly) achieves similar results to daily dosing for maintenance with less total drug exposure.

Intermediate Protocol: Enclomiphene 25 mg with Estradiol Management

For men who had suboptimal response to 12.5 mg daily, or who have higher baseline hypogonadism severity requiring more aggressive HPG axis stimulation, the 25 mg daily protocol is the next step. This protocol incorporates proactive estradiol monitoring and management.

Prerequisites

All prerequisites from the Beginner Protocol, plus:

• At least 6-12 weeks of documented 12.5 mg daily enclomiphene therapy with partial or insufficient response
• Confirmed compliance with the 12.5 mg regimen
• No contraindications to higher-dose SERM therapy

Protocol

• Weeks 1-4: Enclomiphene 25 mg by mouth once daily, taken with food in the morning
• Week 4-6: Comprehensive lab panel including sensitive estradiol
• Weeks 6-12: Continue 25 mg daily if response favorable; titrate if estradiol elevation concerns
• Week 12: Full repeat panel, symptom assessment, decision on maintenance vs. adjustment

Estradiol Management

The 25 mg dose more reliably produces estradiol elevation than 12.5 mg. If sensitive E2 rises above 50-60 pg/mL with symptoms (nipple sensitivity, water retention, mood changes, libido issues):

Option A: Dose reduction

• Return to 12.5 mg daily or 25 mg every other day
• Recheck E2 in 3-4 weeks

Option B: Add aromatase inhibitor (cautious)

• Anastrozole 0.25 mg twice weekly (start low, never higher without clear indication)
• Target E2: 20-35 pg/mL (NOT below 20 pg/mL — E2 deficiency has its own morbidity)
• Recheck E2 in 3-4 weeks
• Reduce AI dose if E2 crashes below 20

Option C: Lifestyle intervention

• If elevated E2 is driven by high body fat or high aromatase activity, weight loss is the durable solution
• GLP-1 agonists can facilitate weight loss and reduce aromatase-rich adipose
• Resistance training and cardiovascular fitness also reduce aromatase burden

Expected Response

• Testosterone: 600-900 ng/dL typical range on 25 mg daily
• LH: 2.5-4x baseline
• Estradiol: 30-55 pg/mL (may require management)
• Symptoms: More robust libido, energy, mood improvement than 12.5 mg in partial responders

Monitoring Schedule

• Baseline and at 4-6 weeks, 3 months, 6 months, then every 6-12 months for maintenance
• If adding AI: check E2 at 4 weeks after AI addition, then quarterly
• Hematocrit quarterly initially, then semi-annually
• Semen analysis at 3-6 months if fertility relevant

Dose Optimization Strategy

Once a stable effective dose is found at 25 mg daily, consider stepping down over 3-6 months:

• 25 mg daily → 25 mg Mon/Wed/Fri with 12.5 mg other days → 12.5 mg daily maintenance
• Goal: minimum effective dose for long-term use
• Many men maintain excellent response on 12.5 mg every other day after initial stabilization

When 25 mg Still Isn't Enough

If 25 mg daily + optimal estradiol management still doesn't achieve adequate testosterone normalization (persistent T <400 ng/dL, insufficient symptom improvement):

• Reconsider diagnosis: Is this really secondary hypogonadism? Check LH carefully. If LH now high on SERM therapy, the testes are the limiting factor (primary hypogonadism) and SERMs won't work.
• Evaluate compliance and absorption: Confirm drug is being taken correctly, appropriate timing, no absorption issues.
• Consider combination therapy: Add hCG 250-500 IU 2-3x weekly to directly stimulate Leydig cells.
• Consider transition to TRT: If patient fertility is not a current or future concern and SERMs are insufficient, TRT is the next logical step.

Do NOT simply push enclomiphene to 50 mg daily or higher — side effects increase substantially and efficacy gains are marginal.

Combination with hCG

For men where enclomiphene alone provides insufficient response but fertility preservation remains priority:

• Enclomiphene 25 mg daily
• hCG 500 IU subcutaneous 2x weekly (Mon/Thurs)
• Monitor: total T, free T, E2, LH (will be confounded by hCG's LH-mimicking activity), hematocrit
• This combination often produces excellent response in men who were sub-responders to either agent alone

Fertility Considerations

On the intermediate protocol, baseline and 3-month semen analyses are particularly important if fertility is a concern:

• Most men will maintain or improve sperm parameters
• A minority may experience transient dips as the HPG axis adjusts — repeat SA in 2-3 months before concluding
• If sperm parameters worsen on therapy, reassess for other fertility factors (varicocele, anatomical issues, thyroid, etc.)

Lifestyle Synergies

Enclomiphene works better when the underlying physiology is supported:

• Weight management: BMI <28 optimal
• Sleep: 7-9 hours; treat any OSA
• Alcohol: Limit to <7 drinks/week; heavy alcohol disrupts HPG axis
• Resistance training: Improves testosterone, body composition, and symptom response
• Micronutrients: Adequate zinc, vitamin D, magnesium support steroidogenesis
• Stress management: Chronic stress elevates cortisol and suppresses HPG axis

Advanced Protocol: Enclomiphene-Based PCT and Combined HPG Axis Restart

This protocol is used by experienced users for post-cycle therapy after anabolic androgenic steroid (AAS) use, or for restarting the HPG axis in men transitioning off long-term TRT. It represents the most aggressive use case for enclomiphene and requires careful planning, thorough monitoring, and usually supervision by a physician experienced in HPG axis management.

Context and Timing

• Post-AAS cycle PCT: Begin after the last dose of exogenous androgen has cleared. Timing depends on ester: testosterone cypionate (14-18 days from last dose), testosterone enanthate (10-14 days), short-ester testosterone propionate (3-5 days), nandrolone decanoate (3-4 weeks), trenbolone (2-3 weeks).
• TRT discontinuation: If planning to come off long-term TRT, consider a 4-8 week transition with hCG to maintain testicular responsiveness before PCT start.
• Pre-PCT labs: Confirm androgens have cleared (total T should be low), LH/FSH suppressed (confirms shutdown), estradiol status, hematocrit, lipids, LFTs.

Phase 1: HPG Axis Priming (Weeks 1-3)

• hCG 1,000-2,500 IU subcutaneous every other day
• Duration: 10-21 days depending on cycle length and severity of suppression
• Purpose: Restart testicular responsiveness that may have regressed during suppression. Without this phase, enclomiphene drives LH/FSH but the testes may be slow to respond.
• Monitor: Initial dose rarely causes acute issues; watch for water retention, mood effects.

Phase 2: SERM PCT (Weeks 3-8)

• Enclomiphene 25 mg daily (some protocols use 50 mg daily for week 1, then 25 mg) for 4-6 weeks
• OR dual SERM: Enclomiphene 12.5 mg daily + Tamoxifen 20 mg daily for 4-6 weeks
• Purpose: Drive HPG axis to maximum output, restore endogenous testosterone production
• Monitor at week 3: Initial response assessment
• Monitor at week 6: Lab panel including total T, LH, FSH, E2, CBC, lipids

Phase 3: Taper (Weeks 8-10)

• Enclomiphene 12.5 mg daily for 2-4 weeks
• Allow HPG axis to settle into self-regulating steady state
• Prepare for discontinuation

Phase 4: Off-Cycle Monitoring (Weeks 10+)

• Discontinue all pharmacology
• Labs at weeks 10, 14, 18, and 24 post-cycle to confirm sustained recovery
• Target: Total T >400 ng/dL, LH/FSH in normal range, normal semen parameters (if relevant)
• If not recovered by month 6, extended evaluation and possible additional intervention

Advanced Variables and Adjustments

Heavy cycles (long duration, multiple compounds, high doses): Extend Phase 1 hCG to 3 weeks, Phase 2 SERM to 6-8 weeks, add or extend low-dose AI, consider third agent like clomiphene or tamoxifen in addition.

Prior suppressed baseline (primary or prolonged secondary): PCT may only partially restore function. Some users require indefinite low-dose SERM or ultimately transition to TRT if HPG axis does not recover.

Rapid recovery goal: Higher doses for shorter durations. Enclomiphene 50 mg daily for 2 weeks then taper. More aggressive, more side effects, not clearly superior to standard dosing for most users.

Estradiol Management in PCT Context

Estradiol can swing wildly during PCT as testosterone rises and falls. Common approach:

• Avoid AI in weeks 1-3 (hCG phase) unless E2 clearly elevated and symptomatic
• Watch for rebound E2 rise in weeks 3-5 as testosterone surges
• Low-dose anastrozole 0.25 mg twice weekly PRN for clear E2 issues
• Do NOT prophylactically crush E2 — estradiol deficiency during PCT causes libido, mood, and joint issues that complicate recovery

Fertility-Focused PCT Variant

For men whose priority is aggressive sperm parameter recovery (pre-conception after cycle):

• hCG 1,500 IU 3x weekly for 3-4 weeks
• Plus FSH supplementation (recombinant FSH or menotropin) 150 IU 3x weekly for 3-4 weeks
• Then enclomiphene 25 mg daily for 6 weeks
• Extended taper to 12.5 mg daily for 8 weeks
• Semen analysis monthly during and for 3 months post
• Often supervised by reproductive urologist

Transition from TRT to Enclomiphene

For men on stable TRT who want to attempt transition to endogenous production (either for fertility goals or TRT discontinuation):

• Week -2 to 0 pre-transition: Continue TRT at lower dose while initiating hCG 1,000 IU every other day to restart testicular responsiveness
• Week 0: Discontinue TRT (last dose of short-ester) OR allow long-ester to clear over the clearance window
• Weeks 1-3: hCG 1,000 IU every other day, monitoring for testicular response (testicular volume recovery, early LH/FSH/T signs)
• Weeks 3-10: Enclomiphene 25 mg daily, taper hCG over weeks 3-5
• Week 10+: Monotherapy enclomiphene 12.5-25 mg daily if satisfactory response; full labs at weeks 6, 12, 24
• Long-term: Either continue enclomiphene maintenance, attempt full discontinuation, or return to TRT if response inadequate

Red Flags Requiring Clinical Intervention

• Vision changes at any point → immediate discontinuation, ophthalmology evaluation
• Significant mood destabilization → reassess drug vs. underlying condition
• Hematocrit >54% → dose reduction or phlebotomy consideration
• PSA rise >0.5 ng/mL in 6 months → urology evaluation
• Persistent failure to recover HPG axis at 6 months post-PCT → endocrinology referral
• New onset gynecomastia → estradiol assessment, possible SERM continuation or AI addition
• Cardiovascular symptoms → cardiology evaluation, consider discontinuation

The "Bridge" Approach (Controversial)

Some advanced users pursue a "bridge" between cycles or on TRT: low-dose enclomiphene 12.5 mg 2-3x weekly while on blast-level testosterone, attempting to maintain some HPG axis tone and testicular function. This is not supported by trial data, but clinical experience in some practices suggests it may preserve testicular volume and fertility markers more than TRT monotherapy. The trade-off is additional pharmacology burden and uncertain long-term safety. hCG is the more conventional (and better-studied) "bridge" agent.

Experience-Dependent Discretion

Advanced protocols require accurate self-assessment and honest lab interpretation. A PCT that "feels" successful but shows T of 350 ng/dL and suppressed LH six months post-cycle is not a success. Return to baseline (or better) with self-sustaining HPG axis function is the actual endpoint. Men who repeatedly require pharmacological support to maintain acceptable testosterone should seriously consider whether TRT is the more appropriate long-term path, rather than endlessly cycling SERMs with diminishing returns and escalating complexity.